2026 Global: Antiviral Drugs Market -Competitive Review (2032) report
Description
The 2026 Global: Antiviral Drugs Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antiviral drugs market by geography and historical trend. The scope of the report extends to sizing of the antiviral drugs market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Gilead Sciences, Merck & Co., GlaxoSmithKline (GSK), Pfizer, AbbVie, Roche, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, and ViiV Healthcare rank among the ten major companies shaping the global antiviral drugs market, each contributing leading products, pipelines, or platform technologies that address HIV, hepatitis, COVID‑19, RSV and other viral diseases. Gilead is a cornerstone in antivirals with high-profile HIV regimens such as Biktarvy and the COVID‑19 antiviral Veklury (remdesivir), sustaining strong infectious‑disease revenues and continued R&D focus on broad antiviral programs. Merck combines a deep antiviral portfolio and vaccine leadership—its large-scale revenues and pipeline investments support antiviral discovery and commercialization across multiple indications. GSK and ViiV Healthcare (majority‑owned by GSK) are pivotal in HIV and respiratory virus prevention, with ViiV’s antiretroviral regimens and GSK’s long‑acting monoclonal antibodies and vaccine capabilities playing central roles in market dynamics.
Pfizer and AbbVie exert substantial influence through blockbuster antiviral products and rapid pandemic‑era responses: Pfizer’s Paxlovid (nirmatrelvir/ritonavir) and its COVID‑19 vaccine Comirnaty delivered major antiviral sales and reshaped acute‑care antiviral access models, while AbbVie’s hepatitis C therapy Mavyret and extensive antiviral portfolio sustain its market position. Roche contributes via antiviral and diagnostic synergies that support treatment targeting and patient stratification, leveraging its global presence in infectious disease therapeutics and diagnostics. Johnson & Johnson and Bristol‑Myers Squibb add depth with antiviral assets, combination therapies, and integrated development capabilities—J&J’s broad infectious‑disease footprint and BMS’s antiviral research collaborations and therapeutic contributions enhance competitiveness across chronic and acute viral indications. AstraZeneca’s RSV antibody Beyfortus and investments in respiratory and systemic antiviral strategies underscore its growing role in pediatric and adult viral disease prevention and treatment.
These ten companies collectively drive innovation through large R&D budgets, strategic acquisitions, and partnerships that accelerate small‑molecule antivirals, monoclonal antibodies, long‑acting formulations, and vaccine platforms while shaping market access and pricing dynamics worldwide. Geographic reach—especially strong U.S. and European commercial infrastructures—permits rapid scale‑up and distribution of antiviral therapies, contributing to North America’s leading market share in the antiviral drugs sector. Market reports and product sales rankings highlight concentration around a few dominant players whose flagship antivirals and vaccines generate the bulk of revenue, even as mid‑sized and regional pharmaceutical firms and biotech startups supply niche HCV, HIV, RSV and emerging‑virus solutions that influence competition and therapeutic choice.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antiviral drugs market by geography and historical trend. The scope of the report extends to sizing of the antiviral drugs market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Gilead Sciences, Merck & Co., GlaxoSmithKline (GSK), Pfizer, AbbVie, Roche, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, and ViiV Healthcare rank among the ten major companies shaping the global antiviral drugs market, each contributing leading products, pipelines, or platform technologies that address HIV, hepatitis, COVID‑19, RSV and other viral diseases. Gilead is a cornerstone in antivirals with high-profile HIV regimens such as Biktarvy and the COVID‑19 antiviral Veklury (remdesivir), sustaining strong infectious‑disease revenues and continued R&D focus on broad antiviral programs. Merck combines a deep antiviral portfolio and vaccine leadership—its large-scale revenues and pipeline investments support antiviral discovery and commercialization across multiple indications. GSK and ViiV Healthcare (majority‑owned by GSK) are pivotal in HIV and respiratory virus prevention, with ViiV’s antiretroviral regimens and GSK’s long‑acting monoclonal antibodies and vaccine capabilities playing central roles in market dynamics.
Pfizer and AbbVie exert substantial influence through blockbuster antiviral products and rapid pandemic‑era responses: Pfizer’s Paxlovid (nirmatrelvir/ritonavir) and its COVID‑19 vaccine Comirnaty delivered major antiviral sales and reshaped acute‑care antiviral access models, while AbbVie’s hepatitis C therapy Mavyret and extensive antiviral portfolio sustain its market position. Roche contributes via antiviral and diagnostic synergies that support treatment targeting and patient stratification, leveraging its global presence in infectious disease therapeutics and diagnostics. Johnson & Johnson and Bristol‑Myers Squibb add depth with antiviral assets, combination therapies, and integrated development capabilities—J&J’s broad infectious‑disease footprint and BMS’s antiviral research collaborations and therapeutic contributions enhance competitiveness across chronic and acute viral indications. AstraZeneca’s RSV antibody Beyfortus and investments in respiratory and systemic antiviral strategies underscore its growing role in pediatric and adult viral disease prevention and treatment.
These ten companies collectively drive innovation through large R&D budgets, strategic acquisitions, and partnerships that accelerate small‑molecule antivirals, monoclonal antibodies, long‑acting formulations, and vaccine platforms while shaping market access and pricing dynamics worldwide. Geographic reach—especially strong U.S. and European commercial infrastructures—permits rapid scale‑up and distribution of antiviral therapies, contributing to North America’s leading market share in the antiviral drugs sector. Market reports and product sales rankings highlight concentration around a few dominant players whose flagship antivirals and vaccines generate the bulk of revenue, even as mid‑sized and regional pharmaceutical firms and biotech startups supply niche HCV, HIV, RSV and emerging‑virus solutions that influence competition and therapeutic choice.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.